Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Studying samples of blood in the laboratory from patients receiving oxaliplatin
for cancer may help doctors learn more about changes that occur in DNA and identify
biomarkers related to neurotoxicity.
PURPOSE: This phase II trial is studying biomarkers in predicting neurotoxicity in patients
with colorectal cancer receiving oxaliplatin.